254 related articles for article (PubMed ID: 27941882)
1. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Volpin F; Casaos J; Sesen J; Mangraviti A; Choi J; Gorelick N; Frikeche J; Lott T; Felder R; Scotland SJ; Eisinger-Mathason TSK; Brem H; Tyler B; Skuli N
Oncogene; 2017 May; 36(21):3037-3047. PubMed ID: 27941882
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
[TBL] [Abstract][Full Text] [Related]
3. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
4. Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.
Sesen J; Dahan P; Scotland SJ; Saland E; Dang VT; Lemarié A; Tyler BM; Brem H; Toulas C; Cohen-Jonathan Moyal E; Sarry JE; Skuli N
PLoS One; 2015; 10(4):e0123721. PubMed ID: 25867026
[TBL] [Abstract][Full Text] [Related]
5. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
Yahyanejad S; King H; Iglesias VS; Granton PV; Barbeau LM; van Hoof SJ; Groot AJ; Habets R; Prickaerts J; Chalmers AJ; Eekers DB; Theys J; Short SC; Verhaegen F; Vooijs M
Oncotarget; 2016 Jul; 7(27):41251-41264. PubMed ID: 27183910
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
7. Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
Proske J; Walter L; Bumes E; Hutterer M; Vollmann-Zwerenz A; Eyüpoglu IY; Savaskan NE; Seliger C; Hau P; Uhl M
Anticancer Res; 2016 Mar; 36(3):899-905. PubMed ID: 26976976
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Asparaginase
Sanghez V; Chen M; Li S; Chou TF; Iacovino M; Lin HJ; Lasky JL; Panosyan EH
Anticancer Res; 2018 May; 38(5):2627-2634. PubMed ID: 29715082
[TBL] [Abstract][Full Text] [Related]
9. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Huang TT; Hlavaty J; Ostertag D; Espinoza FL; Martin B; Petznek H; Rodriguez-Aguirre M; Ibañez CE; Kasahara N; Gunzburg W; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Cancer Gene Ther; 2013 Oct; 20(10):544-51. PubMed ID: 23969884
[TBL] [Abstract][Full Text] [Related]
10. Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Yokosawa M; Sonoda Y; Sugiyama S; Saito R; Yamashita Y; Nishihara M; Satoh T; Kumabe T; Yokoyama M; Tominaga T
Tohoku J Exp Med; 2010 Aug; 221(4):257-64. PubMed ID: 20622491
[TBL] [Abstract][Full Text] [Related]
11. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
12. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.
Lefranc F; James S; Camby I; Gaussin JF; Darro F; Brotchi J; Gabius J; Kiss R
J Neurosurg; 2005 Apr; 102(4):706-14. PubMed ID: 15871514
[TBL] [Abstract][Full Text] [Related]
13. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Oliva CR; Zhang W; Langford C; Suto MJ; Griguer CE
Oncotarget; 2017 Jun; 8(23):37568-37583. PubMed ID: 28455961
[TBL] [Abstract][Full Text] [Related]
14. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
15. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
Mathieu V; De Nève N; Le Mercier M; Dewelle J; Gaussin JF; Dehoux M; Kiss R; Lefranc F
Neoplasia; 2008 Dec; 10(12):1383-92. PubMed ID: 19048117
[TBL] [Abstract][Full Text] [Related]
16. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
[TBL] [Abstract][Full Text] [Related]
17. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
18. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Garros-Regulez L; Aldaz P; Arrizabalaga O; Moncho-Amor V; Carrasco-Garcia E; Manterola L; Moreno-Cugnon L; Barrena C; Villanua J; Ruiz I; Pollard S; Lovell-Badge R; Sampron N; Garcia I; Matheu A
Expert Opin Ther Targets; 2016; 20(4):393-405. PubMed ID: 26878385
[TBL] [Abstract][Full Text] [Related]
19. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Chakrabarti M; Ray SK
Apoptosis; 2016 Mar; 21(3):312-28. PubMed ID: 26573275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
